Table 3.
Seroconversion of patients on RRT after two doses of BNT162b2 and a single dose of 100 µg mRNA-1273 after adjusting for adequate virus neutralization
| All patients | Haemodialysis | Peritoneal dialysis | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ROC ≥ 30% (≥103 U/mL) | n | % | Sero revers., n/N (%) | n | % | Sero revers., n/N (%) | n | % | Sero revers., n/N (%) | P-value |
| After first vaccine dose | 2/81 | 2.5 | n.a. | 1/75 | 1.3 | n.a. | 1/6 | 16.7 | n.a. | .1481 |
| 4 weeks after complete vaccination | 113/165 | 68.5 | 0/2 | 92/141 | 65.2 | 0/1 | 21/24 | 87.5 | 0/1 | .0534 |
| 10–12 weeks after complete vaccination | 94/181 | 51.9 | 24/156 (15.4) | 80/160 | 50 | 20/137 (14.6) | 14/21 | 65.7 | 4/19 (21.1) | .2282 |
| Prior to booster vaccination | 73/166 | 44.0 | 18/160 (11.3) | 65/150 | (31.3) | 15/147 (10.2) | 8/16 | 50 | 3/13 (23) | .8059 |
| 4 weeks after booster vaccination | 144/148 | 97.3 | n.a. | 130/134 | 97.0 | n.a. | 14/14 | 100 | n.a. | >.999 |
| All patients | Haemodialysis | Peritoneal dialysis | ||||||||
| ROC ≥ 70% (≥196 U/mL) | n | % | Sero revers., n/N (%) | n | % | Sero revers., n/N (%) | n | % | Sero revers., n/N (%) | P-value |
| After first vaccine dose | 1/81 | 1.2 | n.a. | 0/75 | 1.3 | n.a. | 1/6 | 16.7 | n.a. | .0741 |
| 4 weeks after complete vaccination | 100/165 | 60.6 | n.a. | 80/141 | 56.7 | n.a. | 20/24 | 83.3 | n.a. | .0252 |
| 10–12 weeks after complete vaccination | 64/181 | 35.4 | 34/156 (21.8) | 57/160 | 35.6 | 25/137 (18.2) | 7/21 | 33.3 | 9/19 (47.4) | >.999 |
| Prior to booster vaccination | 51/166 | 30.7 | 13/140 (9.3) | 44/150 | 29.3 | 1/12 (8.3) | 7/16 | 43.8 | 1/12 (8.3) | .2602 |
| 4 weeks after booster vaccination | 144/148 | 97.3 | n.a. | 130/134 | 97.0 | n.a. | 14/14 | 100 | n.a. | >.999 |
A total of 103 U/mL of SARS-CoV-2-S-Abs demonstrated an inhibition of ≥30% in the SARSCoV-2-NT-Ab assay, which corresponds to the cut-off for positivity recommended by the manufacturer. At least 70% signal reduction in this assay correlates with a higher likelihood of virus neutralization, with a titre ≥1:20 in the PRNT. This resulted in a SARS-CoV-2-S-AB level of 196 U/mL after ROC analysis. Sero-reversion was determined in patients with at least two consecutive measurements of anti-SARS-CoV-2-S-Abs. Sero revers., sero reversion; n.a., not applicable.
aComparison of seroconversion between haemodialysis versus peritoneal dialysis patients.